Hubei Guangji Pharmaceutical (000952.SZ) released its semi-annual report for 2024. During the reporting period, the company achieved revenue...
According to the report, Hubei Guangji Pharmaceutical (000952.SZ) published its semi-annual report for 2024. During the reporting period, the company achieved revenue of 0.296 billion yuan, a decrease of 13.80% compared to the same period last year. The net loss attributable to shareholders of the listed company was 0.107 billion yuan, and the net loss after deducting non-recurring gains and losses attributable to shareholders of the listed company was 0.116 billion yuan. The basic loss per share was 0.3014 yuan.